Heart Failure With Preserved Ejection Fraction Clinical Trial
— CHiEFOfficial title:
Role of Clonal Hematopoiesis of Indeterminate Potential in Endothelial Dysfunction Associated With Heart Failure With Preserved Ejection Fraction
This study aims at identifying processes that are deregulated in blood cells by Clonal Hematopoiesis of Indeterminate Potential (CHIP) which are involved in the development of heart failure with preserved ejection fraction (HEpEF).
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | February 1, 2026 |
Est. primary completion date | May 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 85 Years |
Eligibility | Inclusion Criteria: - HFpEF group and control group - male or female - 50 = age = 85 ans - Absence of evidence of hematological malignancy (known or obvious by the results of blood counts) - Subject registered with a social security scheme - Written informed consent obtained - HFpEF group - patients with a diagnosis of HFpEF according to the criteria defined by the European society of cardiology - Control group - patients with a neuro-cardiovascular pathology without any link to coronaropathy nor heart failure Exclusion Criteria: - Hematological malignancy (known or obvious on the results of blood counts) - Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases) - Long term anti-inflammatory treatments: - Corticoids - Nonsteroidal anti-inflammatory drugs - Aspirin (> 325 mg per day) - Cyclo-oxygenase II inhibitors - Persons under judicial safeguards, trustee or curatorship - Person deprived of judicial or administrative freedom - Person unable to give her consent - Non-cooperative person - Exclusion period after another clinical study or participation to another interventional clinical study testing a drug in the 30 days before inclusion |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux | INSERM - UMR 1219 |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence of clonal hematopoiesis indeterminate potential (CHIP) | Presence of CHIP defined as the presence of a mutation with an allele frequency greater than 2%. | Inclusion Visit | |
Secondary | Diagnosis of heart failure with preserved ejection fraction | Diagnosis based on the European Society of Cardiology diagnostic sequence | Inclusion Visit | |
Secondary | scRNA-seq analysis | Sixteen patients will be selected for scRNA-seq analysis: 3 patients with HFpEF and TET2 mutation 3 patients with HFpEF and DNMT3A mutation 2 patients with HFpEF but without CHIP 3 patients with TET2 mutation but without HFpEF 3 patients with DNMT3A mutation but without HFpEF 2 patients without HFpEF nor CHIP |
6 months (+/- 3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05839730 -
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05095688 -
Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
|
||
Recruiting |
NCT06379152 -
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT05676684 -
Dapagliflozin, Spironolactone or Both for HFpEF
|
Phase 2/Phase 3 | |
Recruiting |
NCT04153136 -
Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)
|
Phase 2 | |
Recruiting |
NCT05715697 -
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT06114498 -
Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
|
||
Recruiting |
NCT04745013 -
PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart
|
N/A | |
Completed |
NCT05586828 -
A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
|
||
Completed |
NCT05126836 -
Cilostazol for HFpEF
|
Phase 2 | |
Recruiting |
NCT04594499 -
The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
|
||
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Completed |
NCT04535726 -
The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
|
||
Recruiting |
NCT03550235 -
Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
|
||
Completed |
NCT04633460 -
Acute Effects of Exogenous Ketone Ester Administration in Heart Failure
|
Phase 2 | |
Completed |
NCT06228807 -
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
|
||
Active, not recruiting |
NCT05284617 -
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
|
Phase 2 | |
Recruiting |
NCT05562063 -
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
|
Phase 4 | |
Recruiting |
NCT06027307 -
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
|
Phase 3 | |
Withdrawn |
NCT05322616 -
Single-Ascending Dose Study of JK07 in Subjects With HFpEF
|
Phase 1 |